S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Can-Fite BioPharma Stock Forecast, Price & News

-0.08 (-6.20%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
643,506 shs
Average Volume
734,141 shs
Market Capitalization
$32.90 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Can-Fite BioPharma logo

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for cancer and inflammatory diseases. Its product pipeline includes Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.


Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Short Interest Update
January 9, 2022 |  americanbankingnews.com
Can-Fite Issues Letter to Shareholders
January 5, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$760 thousand
Book Value
$0.39 per share


Net Income
$-14.44 million
Net Margins
Pretax Margin




Free Float
Market Cap
$32.90 million

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.78 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Can-Fite BioPharma (NYSEAMERICAN:CANF) Frequently Asked Questions

Is Can-Fite BioPharma a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Can-Fite BioPharma stock.
View analyst ratings for Can-Fite BioPharma
or view top-rated stocks.

How has Can-Fite BioPharma's stock been impacted by COVID-19?

Can-Fite BioPharma's stock was trading at $1.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CANF stock has decreased by 20.4% and is now trading at $1.21.
View which stocks have been most impacted by COVID-19

Are investors shorting Can-Fite BioPharma?

Can-Fite BioPharma saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 4,460,000 shares, an increase of 1,231.7% from the December 15th total of 334,900 shares. Based on an average daily trading volume, of 3,760,000 shares, the short-interest ratio is currently 1.2 days.
View Can-Fite BioPharma's Short Interest

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) released its earnings results on Tuesday, November, 30th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.10. The biotechnology company earned $0.25 million during the quarter. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 183.50% and a negative net margin of 1,518.15%.
View Can-Fite BioPharma's earnings history

What price target have analysts set for CANF?

3 brokers have issued 1 year price objectives for Can-Fite BioPharma's shares. Their forecasts range from $5.00 to $8.25. On average, they anticipate Can-Fite BioPharma's stock price to reach $6.08 in the next twelve months. This suggests a possible upside of 402.8% from the stock's current price.
View analysts' price targets for Can-Fite BioPharma
or view top-rated stocks among Wall Street analysts.

Who are Can-Fite BioPharma's key executives?

Can-Fite BioPharma's management team includes the following people:
  • Pnina Fishman, Chief Executive Officer & Director
  • Motti Farbstein, Chief Financial & Operating Officer
  • Zivit Harpaz, Director-Regulatory & Clinical Operations
  • Michael Silverman, Medical Director
  • Sari Fishman, Vice President-Business Development

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Can-Fite BioPharma investors own include OPKO Health (OPK), Advanced Micro Devices (AMD), BioLineRx (BLRX), Genocea Biosciences (GNCA), Arbutus Biopharma (ABUS), Biocept (BIOC), Pfizer (PFE), Protalix BioTherapeutics (PLX), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How do I buy shares of Can-Fite BioPharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Can-Fite BioPharma's stock price today?

One share of CANF stock can currently be purchased for approximately $1.21.

How much money does Can-Fite BioPharma make?

Can-Fite BioPharma has a market capitalization of $32.90 million and generates $760 thousand in revenue each year. The biotechnology company earns $-14.44 million in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Can-Fite BioPharma have?

Can-Fite BioPharma employs 2,020 workers across the globe.

What is Can-Fite BioPharma's official website?

The official website for Can-Fite BioPharma is www.canfite.co.il.

Where are Can-Fite BioPharma's headquarters?

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at (723) 924-1114, via email at [email protected], or via fax at 972-3924-9378.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.